A detailed history of Efg Asset Management (North America) Corp. transactions in Cytokinetics Inc stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 34,234 shares of CYTK stock, worth $1.68 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
34,234
Previous 31,766 7.77%
Holding current value
$1.68 Million
Previous $1.72 Million 5.0%
% of portfolio
0.31%
Previous 0.3%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.22 - $60.16 $126,410 - $148,474
2,468 Added 7.77%
34,234 $1.81 Million
Q2 2024

Jul 25, 2024

BUY
$47.86 - $75.05 $7,179 - $11,257
150 Added 0.47%
31,766 $1.72 Million
Q1 2024

May 13, 2024

SELL
$63.75 - $108.06 $38,377 - $65,052
-602 Reduced 1.87%
31,616 $2.22 Million
Q4 2023

Feb 08, 2024

SELL
$26.88 - $83.49 $93,676 - $290,962
-3,485 Reduced 9.76%
32,218 $2.69 Million
Q3 2023

Nov 02, 2023

SELL
$29.46 - $36.61 $100,429 - $124,803
-3,409 Reduced 8.72%
35,703 $1.05 Million
Q2 2023

Jul 28, 2023

SELL
$32.62 - $40.75 $75,482 - $94,295
-2,314 Reduced 5.59%
39,112 $1.28 Million
Q1 2023

Apr 27, 2023

SELL
$33.36 - $45.71 $77,395 - $106,047
-2,320 Reduced 5.3%
41,426 $1.46 Million
Q4 2022

Feb 03, 2023

BUY
$35.77 - $51.11 $461,325 - $659,165
12,897 Added 41.81%
43,746 $2 Million
Q3 2022

Oct 28, 2022

SELL
$38.54 - $54.52 $89,451 - $126,540
-2,321 Reduced 7.0%
30,849 $1.49 Million
Q2 2022

Aug 04, 2022

SELL
$33.93 - $48.92 $96,564 - $139,226
-2,846 Reduced 7.9%
33,170 $1.3 Million
Q1 2022

Apr 26, 2022

SELL
$29.74 - $46.0 $14,007 - $21,666
-471 Reduced 1.29%
36,016 $1.33 Million
Q4 2021

Feb 18, 2022

BUY
$34.35 - $46.38 $1.25 Million - $1.69 Million
36,487 New
36,487 $1.66 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.62B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.